Sort   by:  
 Page size 
ProteomicsDown Syndrome and Alzheimer Disease CSF Proteome
Almost all individuals with Down Syndrome (DS) develop Alzheimer’s disease (AD) by mid to late life. However, the degree to which AD in DS shares pathological changes with sporadic late-onset AD (LOAD) and autosomal dominant AD (ADAD) beyond core AD biomarkers such as amyloid-β (Aβ) and tau is unkno...
ORGANISM(S): Homo sapiens (Human) 
2025-07-08 | PXD064699 | Pride
Estimated year of onset Csf proteomics Down's syndrome 
UnknownCortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy.
Not available
S-EPMC6439330 | biostudies-literature
UnknownPrevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Not available
S-EPMC10401753 | biostudies-literature
UnknownAtrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease.
Not available
S-EPMC8493660 | biostudies-literature
ProteomicsComparison of the Amyloid Plaque Proteome in Down Syndrome and Alzheimers Disease
Using unbiased localized proteomics, we analyzed amyloid plaques and adjacent plaque-devoid tissue (non-plaque) from post-mortem paraffin-embedded tissues in three cohorts (n=20/group): Down Syndrome, Early Onset AD, and Late Onset AD. We assessed functional associations using Gene Ontology (GO) enr...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2024-05-18 | MSV000094800 | MassIVE
UnknownCerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami.
Not available
S-EPMC4420868 | biostudies-literature
UnknownInvestigation of the genetic aetiology of Lewy body diseases with and without dementia.
Not available
S-EPMC11228432 | biostudies-literature
UnknownRare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis.
Not available
S-EPMC3775809 | biostudies-literature
UnknownIncreased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
Not available
S-EPMC11779843 | biostudies-literature
UnknownAmyloid-negative neuropsychological norms: Added value in the era of biomarkers and disease-modifying therapies.
Not available
S-EPMC12689264 | biostudies-literature
Sort   by:  
 Page size